NIKKEI 225
37,068.35 -1,011.35 (-2.66%) HANG SENG
16,207.81 -178.06 (-1.09%) CRUDE OIL
83.87 +1.14 (+1.38%) GOLD FUTURES
2,396.90 -1.10 (-0.05%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
51,317.47 +2,258.60 (+4.60%)
Appili Therapeutics Inc. (APLIF)
| Previous close | 0.0292 |
| Open | 0.0292 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0292 - 0.0292 |
| 52-week range | 0.0160 - 0.0760 |
| Volume | |
| Avg. volume | 233,945 |
| Market cap | 3.541M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings date | 21 Jun 2024 - 25 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.15 |
- Business Wire
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
MOUNTAIN VIEW, Calif., April 02, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. Under the Arrangement Agree
GlobeNewswireAppili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical counter
- GlobeNewswire
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
A review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia in UkraineHALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia. Appili’s D
